Gallbladder Cancer Treatment Market Size, Share & Industry Analysis, By Drug (Gemcitabine, Cisplatin, Durvalumab, Pembrolizumab, and Others), By Drug Class (Antimetabolites, Platinum Compounds, PD-1 Inhibitors, PD-L1 Inhibitors, and Antibody-Drug Conjugates), By Therapy (Chemotherapy, Immunotherapy, and Targeted Therapy), By Route of Administration (Parenteral and Oral), By Age Group (Adults and Pediatric), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, and Retail Pharmacies), and Regional Forecast, 2026-2034

Last Updated: September 14, 2026 | Format: PDF | Report ID: FBI101001

Buy Now

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2021-2034
Base Year	2025
Estimated Year	2026
Forecast Period	2026-2034
Historical Period	2021-2024
Growth Rate	CAGR of 10.51% from 2026 to 2034
Unit	Value (USD Million)
Segmentation	By Drug, Drug Class, Therapy, Route of Administration, Age Group, Distribution Channel, and Region
By Drug	Gemcitabine Cisplatin Durvalumab Pembrolizumab Capecitabine Oxaliplatin Fluorouracil Zanidatamab Trastuzumab Deruxtecan Others
By Drug Class	Antimetabolites Platinum Compounds PD-1 Inhibitors PD-L1 Inhibitors Bispecific Antibodies Antibody-Drug Conjugates Topoisomerase Inhibitors Taxanes Others
By Therapy	Chemotherapy Immunotherapy Targeted Therapy Others
By Route of Administration	Parenteral Oral
By Age Group	Adults Pediatric
By Distribution Channel	Hospital Pharmacies Specialty Pharmacies Drug Stores & Retail Pharmacies Online Pharmacies
By Region	North America (By Drug, Drug Class, Therapy, Route of Administration, Age Group, Distribution Channel, and Country) U.S. Canada Europe (By Drug, Drug Class, Therapy, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region) Germany U.K. France Spain Italy Scandinavia Rest of Europe Asia Pacific (By Drug, Drug Class, Therapy, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region) China Japan India Australia Southeast Asia Rest of Asia Pacific Latin America (By Drug, Drug Class, Therapy, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region) Brazil Mexico Rest of Latin America Middle East & Africa (By Drug, Drug Class, Therapy, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region) GCC South Africa Rest of Middle East & Africa